![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RM Denney, RR Fritz, NT Patel, SG Widen and CW Abell
Monoamine oxidase B (MAO B; EC 1.4.3.4) activity in detergent extracts of mitochondria from autopsy brain (gray matter and medulla), liver, lung, and kidney from a single individual and from pooled, human platelets could be immunoprecipitated by a monoclonal anti-human platelet MAO B antibody (MAO-1C2) in combination with appropriate secondary reagents. MAO A activity, which was detected in brain, liver, lung, and kidney, was not immunoprecipitated under the same conditions. All MAO B-containing extracts, regardless of tissue source, inhibited immunoprecipitation of [3H]pargyline-labeled human platelet MAO, and the shapes of the inhibition curves were identical. The concentration of immunologically detectable MAO B protein in the extracts was estimated from immunoprecipitation competition data by reference to a standard curve relating observed inhibition of immunoprecipitation to the concentration of catalytically active platelet MAO added (estimated from [3H]pargyline binding data). MAO B protein concentrations measured by this radioimmunoassay were similar to concentrations of active MAO B as measured by pargyline binding. These results demonstrate that in the brain and peripheral tissues studied, molecules with MAO B activity share a unique antigenic determinant and similar catalytic efficiency. They also extend previous observations that MAO B molecules extracted from mitochondria bear an antigenic determinant which is not present on MAO A molecules. These results demonstrate the validity of a new competitive radioimmunoassay for active plus inactive MAO B concentration in human platelet extracts and extracts of mitochondria from human tissues. This radioimmunoassay should complement [3H]pargyline binding assays and enzyme activity assays in studies designed to clarify the mechanisms of genetic, disease, and treatment factors which lead to differences in MAO B function among individuals.
This article has been cited by other articles:
|
|
 |
|
  J. W. Lohr, G. R. Willsky, and M. A. Acara Renal Drug Metabolism Pharmacol. Rev., March 1, 1998; 50(1): 107 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Raddatz, A. Parini, and S. M. Lanier Imidazoline/Guanidinium Binding Domains on Monoamine Oxidases J. Biol. Chem., November 17, 1995; 270(46): 27961 - 27968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Zhou, D. A. Lewis, S.-W. Kwan, and C. W. Abell Flavinylation of Monoamine Oxidase B J. Biol. Chem., October 6, 1995; 270(40): 23653 - 23660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Westlund, R. Denney, L. Kochersperger, R. Rose, and C. Abell Distinct monoamine oxidase A and B populations in primate brain Science, October 11, 1985; 230(4722): 181 - 183. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
